Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb to publish belatacept trial data

Bristol-Myers Squibb to publish belatacept trial data

27th April 2011

Bristol-Myers Squibb is to publish new clinical data that highlights the potential benefits its drug belatacept can provide for kidney transplant patients.

The company will attend the forthcoming American Transplant Congress in Philadelphia to showcase results from the recent phase III clinical programme Benefit, which evaluated the efficacy of the drug compared to cyclosporine.

Data will be presented that illuminates the safety and efficacy profile of the new treatment, which has been developed as part of Bristol-Myers Squibb's strategy of creating targeted therapies for serious disease.

Dr Brian Daniels, senior vice-president for global development and medical affairs at the company, noted that the period following surgery currently poses numerous medical challenges for transplant patients.

He added: "The breadth of Bristol-Myers Squibb's clinical data on belatacept at the American Transplant Congress demonstrates our ongoing commitment to address the unmet medical needs of patients in the renal transplant community."

Last month, the firm published positive new clinical trial data for ipilimumab, its new therapy for metastatic melanoma.ADNFCR-8000103-ID-800512679-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.